The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Spanish plasma-based medicines maker Grifols (MCE: GRF) has announced disappointing top-line data from its Phase III PRECIOSA clinical trial evaluating the potential of long-term albumin treatment ...

Since April, Grifols has been collecting blood plasma donated by healthy people who have recovered from COVID-19. The company processes plasma, collected at its 300-plus donation centers, to yield ...

Heating plasma to the ultra-high temperatures needed for fusion reactions requires more than turning the dial on a thermostat. Scientists consider multiple methods, one of which involves injecting ...

One of their biggest roster weaknesses is the center position, where they lack a strong backup behind Anthony Davis and don't really have the ability to run lineups with another true big man alongside ...

Scientists would like to track electrical activity in the ionosphere by measuring the distribution of plasma, the form matter takes when positive ions are separated from their electrons ...